, a member of the Cip/Kip family of Cdk inhibitors (Sherr and Roberts, 1999) , which binds to Cdk2 (and to other Cdks) and potently inhibits Cdk2 kinase activity. Therefore, p27 overexpression in human cells leads to cell-cycle arrest in the G1 phase. In quiescent cells (G0 phase), p27 levels are high concomitant with low Cdk activity. As cells enter the cell cycle and S phase, p27 levels decrease and the kinase activity of Cdks increases. p27 is a short-lived protein, and its degradation is controlled by the ubiquitin-proteasome system (Pagano et al., 1995) . Cdk2 (or Cdk1) phosphorylates p27 at threonine 187, which is then recognized by the SCF Skp2 ubiquitin ligase and degraded by the proteasome (reviewed in Bloom and Pagano, 2003) . In addition, there is a different ubiquitin ligase, KPC, which recognizes unphosphorylated p27 during G1 (Kamura et al., 2004) . In this issue of Cell, two papers (Chu et al., 2007; Grimmler et al., 2007) describe a new mechanism of p27 phosphorylation.
In vivo, mice lacking p27 are viable but are bigger than wild-type littermates. p27-deficient mice develop pituitary tumors and in some incidents retinal dysplasia, thymic hyperplasia, female sterility, and hyperplasia of the adrenal gland (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . Therefore, p27 is not an essential gene but is important for growth control in vivo. The cell-cycle kinetics of mouse embryonic fibroblasts lacking p27 is comparable to wild-type counterparts, but their Cdk2 activity is massively elevated. Given that p27 does not seem to inhibit Cdk4 or Cdk6 (Sherr and Roberts, 1999) , most if not all phenotypes of p27-deficient mice were thought to be dependent on increased Cdk2 activity. However, Cdk2 deletion in p27-deficient mice did not rescue p27-deficient phenotypes and lead to the discovery that Cdk1 is an in vivo target for p27 (Aleem et al., 2005) .
Based on these studies, a cell-cycle model was proposed where Cdk activity, which promotes cell-cycle progression, is inhibited by p27, thereby causing cells to arrest. Nevertheless, there are a number of observations that do not fit this model. For example, overexpression of p27 in mouse embryonic fibroblasts and a few human cell lines does not result in complete G1 arrest. In addition, low levels of p27 observed in human tumors do not correlate with the proliferation index (Loda et al., 1997) . Thus, additional functions of p27 may still be uncovered.
Entry into the cell cycle from quiescence is a major decision for cells. In order to activate Cdk/cyclin complexes-which seems essential for cell-cycle entryinactive Cdk/cyclin/p27 complexes need to be converted into active complexes. Several mechanisms (such as transcription and degradation of cyclins, phosphorylation of Cdks, and inhibitors like p27) inhibit Cdk activation in G0. With respect to p27, re-entry into the cell cycle involves phosphorylation on threonine 187, which induces its degradation. Given that there is no detectable Cdk1 (or Cdk2, 3, 4, or 6) activity in G0, it is hard to imagine how p27 can be phosphorylated unless p27 is phosphorylated by other kinases. Possibly a single (perhaps newly synthesized) active Cdk/cyclin complex could start an avalanche-like process in which every single p27 molecule removed from Cdk/cyclin complexes would result in increased Cdk activity and therefore increased phosphorylation of p27. Although such a process cannot be excluded, it is unlikely to be the only mechanism.
Tyrosine Phosphorylation of p27 Initiates Its Degradation Several groups now describe the phosphorylation of p27 on tyrosine residues (Chu et al., 2007; Grimmler et al., 2007; Kardinal et al., 2006) . Grimmler et al. (2007) find that the nonreceptor tyrosine kinase Lyn binds to p27 and phosphorylates it on tyrosine 88 when both proteins are overexpressed in cell lines. The nonreceptor tyrosine kinase Abl also phosphorylates p27 on tyrosine 88 and to a lesser extent on tyrosine 89.
Another Piece of the p27
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Puzzle
Philipp Kaldis 1, Although tyrosine phosphorylation of p27 reduced its ability to inhibit Cdk2 by approximately 10-fold, this version of p27 is still able to bind Cdk2/cyclin A complexes through interactions with cyclin A and Cdk2. NMR analysis indicated that the 3 10 -helix of p27 did not make contact with Cdk2 when p27 was phosphorylated on tyrosine ( Figure 1 ). The 3 10 -helix of p27 contains tyrosine 88, which is normally inserted into the ATP binding site of Cdk2 preventing catalytic activity (Russo et al., 1996) . Therefore, tyrosine-phosphorylated p27 cannot effectively inhibit Cdk2 activity. Grimmler et al. (2007) also detected increased threonine 187 phosphorylation of tyrosine-phosphorylated p27 leading to decreased p27 protein levels presumably through increased ubiquitylation. Mutant p27 Y88F , which cannot be phosphorylated on tyrosine 88, displayed increased stability in cells, probably because phosphorylation of threonine 187 and subsequent degradation would be less efficient. Chu et al. (2007) investigated primary human breast cancers and found a loose correlation between low levels of p27 and activated Src kinase. In vitro, Srcbut not inactivated Src-phosphorylated p27 on tyrosine 74 and 88, which leads to decreased binding to Cdk2. Therefore, tyrosine-phosphorylated p27 is not an efficient inhibitor of Cdk2 activity in comparison to wild-type p27. Inhibition of Src by the phosphatase PP1 or small interfering RNA decreased tyrosine phosphorylation and increased protein stability of p27, which was correlated with decreased phosphorylation of threonine 187. Kardinal et al. (2006) found in human acute promyelotic leukemia NB4 cells that p27 interacts with the G-CSF receptor and Grb2 when p27 was tyrosine-phosphorylated. Treatment with G-CSF leads to decreased p27 tyrosine phosphorylation and diminished interaction with Cdk4, although Cdk2 binding was not affected. Phosphorylation of p27 by Abl increased p27's affinity for Cdk4 while decreasing it for Cdk2.
All three papers indicate that p27 is phosphorylated on tyrosine, resulting in decreased p27 protein stability. The tyrosine residue differs (tyrosine 88 and to some extent 74, 89), but the overall effect seems similar. The interesting aspect is the connection of tyrosine kinases (extracellular signals) to cell-cycle regulation. Such a connection has been thought to exist, but the molecular mechanism had not been determined. The papers discussed here provide evidence for such a mechanism, and this feature should be incorporated in future cell-cycle models. However, these results have to be treated with caution because they were obtained by overexpressing p27 and tyrosine kinases in cell lines and it is unknown whether p27 is tyrosine-phosphorylated in vivo.
In terms of biochemistry and structural biology of Cdk/cyclin/p27 complexes, tyrosine phosphorylation of p27 adds a new dimension. As mentioned, when cells enter the cell cycle, inactive Cdk2/cyclin/p27 complexes have to be converted into active complexes. To achieve this goal there are three possibilities: (1) to degrade p27 through ubiquitin-mediated proteolysis resulting in activation of Cdk2/cyclin complexes, (2) to synthesize new Cdk2 and cyclin molecules without increasing p27 levels, or (3) to propose transient binding of p27 to Cdk complexes through interactions with the cyclin subunit without inhibiting Cdk activity. The first possibility is straightforward but does not explain how p27 can be phosphorylated when bound to Cdk2/cyclin complexes, as there is no measurable Cdk1, 2, 3, 4, and 6 kinase activity available in G0. Tyrosine phosphorylation of p27 by tyrosine kinases provides a mechanism on how to reactivate Cdk2/cyclin complexes when p27 is bound. As mentioned above, tyrosine-phosphorylated p27 remains bound to Cdk2/cyclin complexes, but p27 does not obstruct the ATP binding site of Cdk2, thereby allowing efficient phosphorylation of p27 on threonine 187 by Cdk2 and subsequent p27 degradation (Figure 1) . The second possibility is difficult to prove experimentally. Newly synthesized Cdk2 or cyclins cannot be isolated (2007) and Chu et al. (2007) describe tyrosine phosphorylation of p27 by nonreceptor tyrosine kinases, followed by phosphorylation of p27 on threonine 187 and p27 degradation. Interestingly, p27 phosphorylation by tyrosine kinases results in "active" Cdk complexes that are still bound to p27. Phosphorylation of p27 by tyrosine kinases is a way for extracellular signals to feed into the cell cycle. and separated from existing Cdk2/cyclin/p27 complexes. Perhaps new methods will be developed in the future to address such questions. The third possibility has been suggested by using mutants of p27 that can only interact with cyclins or only Cdks but not with both (Vlach et al., 1997) . Nevertheless, it is conceivable that all possibilities occur simultaneously in vivo.
Unsolved Pieces of the Puzzle
As with all good scientific reports, the current ones raise more new questions than they answer. Among the top issues regarding p27 is the difference between Cdk2 and Cdk4 (or Cdk6). In vivo, the majority of p27 molecules are bound to Cdk4, and only a small proportion of p27 is bound to Cdk2 (there is no free p27 detectable in vivo). Therefore, Cdk4 is a sink for p27 molecules and could be an assembly factor for Cdk4/ cyclin D complexes (LaBaer et al., 1997) . In the past, it has been accepted that p27 is a potent inhibitor of Cdk2. This has been based on the inability to observe Cdk2/cyclin/p27 complexes with measurable kinase activity. The current reports challenge this notion by demonstrating that p27 can bind to Cdk2 without inhibiting its activity. In contrast, active Cdk4/cyclin D/p27 complexes have been reported (Blain et al., 1997; Soos et al., 1996) . Based on these observations, tyrosine phosphorylation of p27 would provide an ideal explanation, if tyrosine-phosphorylated p27 would inhibit Cdk2 but not Cdk4, or if tyrosine-phosphorylated p27 would preferentially bind to Cdk4. Given that Grimmler et al. (2007) and Chu et al. (2007) mostly investigate Cdk2, we can only speculate how tyrosine-phosphorylated p27 is interacting with Cdk4. Based on these two papers, there is no indication that tyrosine-phosphorylated p27 interacts differently with Cdk2 than Cdk4. Kardinal et al. (2006) suggest differential interaction of Cdk2 and Cdk4 with GST-p27. It would be interesting to know whether expression of p27 Y88F does affect the assembly of Cdk4/cyclin D complexes in vivo. Most likely, we have to await further experiments to address the relation of tyrosine-phosphorylated p27 and Cdk4.
Another interesting aspect of these findings deals with the interaction of tyrosine 88 in p27 and the ATP binding site of Cdk2 (Figure 1) . The crystal structure of Cdk2/cyclin A/p27 complexes indicated that tyrosine 88 is buried inside the ATP binding pocket of Cdk2 (Russo et al., 1996) . Based on this, it is hard to imagine how tyrosine kinases are able to phosphorylate tyrosine 88. Nevertheless, Grimmler et al. (2007) demonstrate that this is possible albeit less efficient than phosphorylation of free p27. In this regard, it would be interesting to know which percentage of the total p27 molecules are tyrosine-phosphorylated during the cell-cycle phases. Furthermore, tyrosine-phosphorylated p27 is bound to Cdk2 without inserting into the ATP binding site. This would imply that Cdk2/cyclin/tyrosine-phosphorylated p27 complexes can display comparable activity as Cdk2/cyclin complexes. It should be feasible to determine the binding kinetics of ATP and substrate specificity of these complexes in the future.
Tyrosine phosphorylation leads to increased phosphorylation on threonine 187 and decreased stability of p27. This implies that tyrosine-phosphorylated p27 is more efficiently ubiquitylated by SCF Skp2 . This assumption should be confirmed experimentally because, for example, a knockin of mutant p27 T187A displayed only a mild phenotype in mice (Malek et al., 2001) , although colon adenomas in these animals were less likely to progress to carcinomas (Timmerbeul et al., 2006) . A final issue to be resolved is the timing of p27 phosphorylation on tyrosine and its degradation. Although, the former is assumed to occur minutes after a quiescent population is exposed to mitogens, the latter occurs hours later. Thus, it is not unlikely that there are additional pathways controlling p27 stability (like the ubiquitin ligase KPC).
Phosphorylation of p27 has been studied extensively and the following phosphorylation sites have been described: serine 10; threonine 157 (not conserved in mouse p27), 187, and 198; and now tyrosine 74, 88, and 89 ( Figure S1 ). These phosphorylation events might impinge on the biological functions of p27. For each of the phosphorylation sites, several kinases have been reported and different (at times contradicting) functions have been ascribed. In these studies, there is a common thread leading back to serine 10, which is the major p27 phosphorylation site. Actually, it is estimated that 75% of phosphate incorporation occurs at serine 10, even when activated Lyn is coexpressed (Grimmler et al., 2007) . The importance of serine 10 phosphorylation is corroborated in vivo, since p27 S10A is resistant to Ras-induced translocation into the cytoplasm and p27 S10A knockin mice are less tumor prone (Besson et al., 2006) . In addition, there have been confusing reports concerning the kinases phosphorylating specific residues. In some cases this can be traced back to the source of the recombinant kinase as, for example, it has been shown that Akt from three commercial sources display different substrate specificities (Nacusi and Sheaff, 2006) . Similarly, it is unclear why coexpression of Lyn and p27 Y88F leads to increased threonine 187 phosphorylation (Grimmler et al., 2007) unless Lyn harbors functions that are independent of tyrosine 88.
Tyrosine-Phosphorylated p27 In Vivo and Cancer
The novel finding of tyrosine-phosphorylated p27 is changing our view of p27/Cdk interactions, p27 degradation, and control of the cell cycle by tyrosine kinases. We are left to wonder how tyrosine phosphorylation influences p27 functions in vivo. Chu et al. (2007) show that some human breast cancers are characterized by low p27 levels, which is associated with poor prognosis. One possibility to explain low p27 levels in these cancers are the elevated levels of Cdk activity, which would in turn phosphorylate threonine 187 in p27. This is the basic mechanism of a feedback loop. Now, Chu et al. (2007) provide a new explanation. In a number of cancer samples, a correlation of low p27 with hyperactivated Src kinase was observed. Src would be able to phosphorylate p27 on tyrosine, which leads to decreased levels of p27. This appealing hypothesis might be tested by staining sections of cancers with phospho-tyrosine-p27 antibodies. Most likely though, this is one of many mechanisms that contribute to low p27 levels in cancer. Other means like the feedback loop (mentioned above) and alterations in the ubiquitin pathway are likely to aid Src in keeping p27 levels low. For example, an inverse correlation of Skp2 and p27 expression has been observed in tumors (reviewed in Bloom and Pagano, 2003) . Therefore, staining of the same tumors for Skp2 would be informative.
The other interesting connection is BCR-ABL, an oncogene resulting from the Philadelphia translocation, which causes acute lymphoblastic and chronic myelogenous leukemia. BCR-ABL is a hyperactive form of Abl and phosphorylates p27 on tyrosine. Grimmler et al. (2007) demonstrate that inhibition of BCR-ABL with STI-571 (Gleevec, Imatinib) increases p27 protein levels, which probably results in decreased cell proliferation. Based on this, it would be interesting to know whether the effectiveness of STI-571 to combat cancer is related to stabilization of p27 and whether this applies to all BCR-ABL positive cancers.
The puzzle of p27's in vivo functions has not been solved yet, but based on the new observation of tyrosine phosphorylation in p27 along with many other advances in the p27 field, we expect a bright future. Therefore, manipulating p27 levels in cancer could hold one of the important keys for cancer therapy.
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